#VisualAbstract: Adjuvant Dabrafenib plus Trametinib Improves Outcomes in Stage III Melanoma
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Tag: trametinib
#VisualAbstract: Combination of spartalizumab plus dabrafenib and trametinib does not significantly improve survival in BRAFV600-mutated metastatic melanoma
Click to read this study in the Journal of Clinical Oncology.
Trametinib improves progression-free survival among patients with low-grade serous ovarian carcinoma
1. The median progression-free survival for trametinib was significantly greater than that for standard-of-care therapy (13 months vs. 7.2 months). ...
#VisualAbstract: Combined anti-PD-1 and anti-CTLA-4 blockade improves survival among patients with BRAF-mutated melanoma and elevated LDH
Click to read the study in the European Journal of Cancer.
#VisualAbstract: BRAF and MEK inhibitor combination therapy shows efficacy for advanced melanoma in Japanese patients
Click to read the study in the European Journal of Cancer.
#VisualAbstract: Circulating tumor DNA levels may predict treatment response in patients with advanced melanoma
Click to read the study in The Lancet Oncology.
#VisualAbstract: Durvalumab, trametinib, and dabrafenib triplet therapy may provide robust immunogenicity in patients with BRAF-mutated advanced melanoma
Click to read the study in Nature Communications
Combination trametinib and dabrafenib show fewer side effects for metastatic melanoma than dabrafenib alone
1. In patients undergoing treatment for metastatic melanoma, there was a statistically significant decreased risk of cutaneous toxic effects in ...
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
